OBJECTIVES: Aneurysm re-rupture is associated with significant morbidity and mortality in @entity510 ( @entity510 ). While antifibrinolytics reduce @entity439 re-rupture rates, they have been associated with @entity1276 , delayed @entity2806 , and @entity49 . We performed a case-control study in @entity1 enrolled in the @entity438 @entity916 Angiotensin System (CARAS) study to evaluate the impact of short course (<48h)   -aminocaproic acid ( @entity930 ) on @entity1150 ( @entity1150 ) rates. @entity1 AND METHODS: A case-control study design was utilized to evaluate the effect of @entity930 on @entity1150 formation. All cases and controls were obtained from the CARAS study, a prospective, blinded study assessing the association of polymorphisms in the @entity916 angiotensin system and @entity510 . RESULTS: One hundred and twenty-eight eligible @entity1 were enrolled in CARAS. Overall, 48 (37.5%) @entity1 were screened for @entity1150 , 57 (44.5%) @entity1 were treated with short course (<48h) @entity930 , and 8 (6.3%) @entity1 suffered a re-rupture (4 treated with @entity930 ). Ten @entity1 (7.8%) were diagnosed with @entity1150 as evidenced by Doppler US and represent the cases. Twenty controls without evidence of a @entity1150 matched for age, sex, race, @entity286 history, Hunt-Hess score, Fisher grade, body mass index, and length of stay were identified from the remaining pool of 118 @entity1 . @entity930 was found to significantly increase the risk of @entity1150 formation in @entity1 with @entity510 (OR 8.49, CI 1.27-77.1). CONCLUSION: Short course (<48h) administration of @entity930 in @entity1 with @entity510 is associated with an 8.5 times greater risk of @entity1150 formation.

Antifibrinolytic therapy in XXXX increases the risk for @entity1150 : A case-control study.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity286 :: ('4097', 'Species') :: ['tobacco'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia'] @entity1276 :: ('MESH:D006849', 'Disease') :: ['hydrocephalus'] @entity510 :: ('MESH:D013345', 'Disease') :: ['aneurysmal subarachnoid hemorrhage', 'aSAH'] @entity49 :: ('MESH:D019851', 'Disease') :: ['venous thrombosis'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis', 'DVT'] @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm'] @entity930 :: ('CHEBI:16586', 'Chemical') :: ['EACA'] @entity916 :: ('5972', 'Gene') :: ['Renin', 'renin'] @entity438 :: ('MESH:D002532', 'Disease') :: ['Cerebral Aneurysm']
@entity510 :: (MESH:D013345,Disease) :: ['aneurysmal subarachnoid hemorrhage']
